Toxoplasmosis in bone marrow transplant recipients is a rare but serious complication and if untreated, almost uniformly fatal. The diagnosis, however, remains difficult. We therefore compared serial determination of antibody titers specific for T. gondii before and after transplantation, serial PCR for T. gondii DNA in serum, PCR and nested PCR for T. gondii DNA in various tissues, conventional histology and immunohistochemistry for detection of parasites in three patients with autopsy-confirmed toxoplasmosis after bone marrow transplantation. Immunohistochemistry demonstrated the presence of parasites in 13 out of 20 organs investigated (65%), whereas PCR detected T. gondii-specific DNA in 15 out of 20 organs (75%). Immunohistochemistry revealed concordant results to PCR data in 60% of the specimens. With the use of a nested PCR protocol, eight out of nine samples (89%) were positive for T. gondiispecific DNA. The combination of both methods detected the presence of parasites in 90% of the specimens. Serial PCR in serum did not yield positive results. Neither PCR nor immunohistochemistry was able to detect parasites in all organs investigated, but both methods together improved sensitivity to 90% and consequently, should be used jointly to maximize diagnostic precision. Bone Marrow Transplantation (2000) 25, 1257-1262. Keywords: toxoplasmosis; bone marrow transplantation; PCR; immunohistochemistry; serology Toxoplasma gondii is a protozoon affecting and persisting in almost all known mammals. In man, it is known to invade many cell types causing an asymptomatic infection in the vast majority of immunocompetent individuals. Toxoplasmosis results from reactivation of latent infection when the individual is immunocompromised. The incidence of toxoplasmosis and seropositivity varies considerably between different countries and within distinct geographic regions, depending on local pet habits, especially the presence of cats and food contamination with cysts.
Toxoplasma gondii is a protozoon affecting and persisting in almost all known mammals. In man, it is known to invade many cell types causing an asymptomatic infection in the vast majority of immunocompetent individuals. Toxoplasmosis results from reactivation of latent infection when the individual is immunocompromised. The incidence of toxoplasmosis and seropositivity varies considerably between different countries and within distinct geographic regions, depending on local pet habits, especially the presence of cats and food contamination with cysts. 1 In contrast to patients with other forms of immunosuppression (eg HIV infection), the incidence of toxoplasmosis in bone marrow transplant recipients is low, despite the profound and long lasting immunosuppression during and after bone marrow transplantation (BMT). Until now, 55 cases of disseminated toxoplasmosis following BMT have been reported in the English language literature. 2 After BMT, the rate of toxoplasmosis diagnosed either intra vitam or at autopsy ranges from 0.3% in the United States 3 to 5% in France. 4 Non-invasive diagnosis of toxoplasmosis after BMT is important since the course of untreated toxoplasmosis after BMT is rapid and almost uniformly fatal. 5 Serology after BMT, however, has not been informative, since IgG titers do not rise, and may even decline, during infection 6, 7 and since an IgM response may be lacking. 6 Alternatively, cysts and free tachyzoites could be visualized directly in bronchoalveolar lavage fluid (BAL) 8 or bone marrow aspirates, 9 but this approach carries the risks associated with obtaining samples. Tissue culture methods have a long turnaround time, and animal inoculation methods may substantially delay the diagnosis. 6 Polymerase chain reaction (PCR) has been evaluated as a diagnostic tool suggesting that this method is more sensitive in detecting T. gondii in infected body fluids than the available microscopic methods. 10 Here we report our investigations of three patients with disseminated toxoplasmosis after BMT in which we compared two sensitive methods for diagnosing toxoplasmosis.
Case reports

Patient UPN 596
A 20-year-old man with acute lymphocytic leukemia in second complete remission received a bone marrow transplant from his HLA-identical brother. Serological data for the recipient before BMT and donor for toxoplasmosis are given in Table 1 . Preparative therapy included total body irradiation (3 ϫ 400 cGy), cyclophosphamide (100 mg/kg body weight) and etoposide (50 mg/kg body weight). After BMT, antibiotic prophylaxis consisted of oral ciprofloxacin, amphotericin B, and acyclovir. Prophylaxis against graftversus-host disease (GVHD) was performed with cyclospo- rin (CsA) and a short course of methotrexate. The patient developed grade III acute GVHD at day ϩ16 after BMT and was treated with methylprednisolone. After initial resolution of the symptoms, acute GVHD reappeared requiring increasing doses of corticosteroids and administration of rabbit anti-thymocyte globulin (ATG). The symptoms of GVHD resolved again. At day ϩ85, the patient's mental status deteriorated, and CT and MRT scans of the brain revealed two focal lesions within the right frontal and the temporal lobe, respectively. Toxoplasmosis of the brain was suspected, and systemic therapy with pyrimethamin (50 mg/day) and clindamycin (4 ϫ 600 mg/day) was begun.
In the cerebrospinal fluid (CSF), PCR for toxoplasma was positive at day ϩ90. On the same day, positive PCR results for toxoplasma were obtained in the serum as well. Despite antiparasitic therapy, the patient expired on day ϩ92.
Patient UPN 639
A 37-year-old man suffering from chronic myelogenous leukemia (CML) was transplanted in second chronic phase with bone marrow from an unrelated donor with one minor DRB1 mismatch. Serological data of the recipient before BMT with regard to toxoplasmosis are given in Table 1 . Conditioning therapy included busulfan (10 mg/kg body weight), cyclophosphamide (120 mg/kg body weight), and thiotepa (750 mg/m 2 ) together with rabbit anti-thymocyte globulin (ATG). Prophylaxis against GVHD consisted of CsA and a short course of methotrexate. Antimicrobial prophylaxis was performed as described in patient UPN 596. Engraftment was noted at day ϩ20 for neutrophils and at day ϩ29 for platelets. At day ϩ19 post BMT, the patient showed symptoms of acute grade IV GVHD involving the skin and subsequently the gut and liver. Since treatment with methylprednisolone at 3 mg/kg failed, high-dose methylprednisolone (3 ϫ 250 mg/day) and horse ATG were administered leading to resolution of gut and skin symptoms. However, serum bilirubin remained elevated. At day ϩ28, cytomegalovirus (CMV)-DNA was demonstrated in the peripheral blood by PCR, and antiviral therapy with gancyclovir was initiated. At day ϩ32, the patient developed pneumonia and an acute respiratory distress syndrome which was thought to be related to reactivation of CMV infection. He died on day ϩ34 from progressive respiratory insufficiency and multi-organ failure. At autopsy, various organs including the lungs contained numerous T. gondii pseudocysts.
Patient UPN 676
A 37-year-old man with CML in second chronic phase received a bone marrow transplant from an unrelated donor with one HLA-B antigen mismatch (recipient, HLA-B * 35,Ϫ; donor, HLA-B * 15,35). Serological data of the recipient before BMT with regard to toxoplasmosis are given in Table 1 . Conditioning regimen, post-transplant immunosuppression and antimicrobial prophylaxis were identical to those given to patient UPN 639. Neutropenic fever occurred at day ϩ3 post-BMT. At day ϩ25, he developed grade III acute GVHD with massive watery diarrhea, skin rash, and an increase in serum bilirubin up to 6.0 mg/dl. Treatment with methylprednisolone gradually improved the diarrhea, and the rash as well as the bilirubinemia disappeared.
After discharge from the hospital, the patient had a positive PCR and APAAP reaction for CMV (day ϩ57). He developed fever and clinical and radiologic signs suggestive of interstitial pneumonia. Bronchoscopy done on day ϩ59 revealed inflamed bronchi. Bronchoalveolar lavage was negative for Pneumocystis carinii, fungi and acid-fast rods. Gancyclovir treatment was instituted leading to a resolution of symptoms; PCR and APAAP reaction for CMV became negative.
At day ϩ76 after BMT, a cranial computed tomography was performed because of head-aches, nausea, and vomiting, revealing four lesions which were consistent with cerebral toxoplasmosis. Therapy was instituted with pyrimethamin (75 mg daily), clindamycin (3 ϫ 600 mg), leukovorin, and dexamethasone, which led to a rapid disappearance of the patient's symptoms. Because of pancytopenia, gancyclovir and pyrimethamin were discontinued at days ϩ85 and ϩ119 after BMT, respectively. Control CT scans of the brain at day ϩ90 and day ϩ127 did not show any significant changes in the lesions' size and appearance. A stereotactic biopsy, performed at day ϩ104, revealed necrotizing inflammatory changes but no microorganisms. PCR and immunohistochemistry for T. gondii done on the biopsy specimens were negative. PCR for T. gondii in the cerebrospinal fluid obtained at day ϩ80 and day ϩ111, however, was positive.
At day ϩ126 after BMT, the patient presented with signs of extensive chronic GVHD. Skin changes resolved on prednisone treatment, however, liver function deteriorated. At day ϩ161, he was readmitted with weakness, shortness of breath, loss of appetite, and edema of the feet. He showed symptoms of liver failure and sepsis. Blood cultures were positive for group B streptococci. The patient expired on day ϩ164 after BMT.
Serology
Patient serum samples collected before BMT and at weekly intervals thereafter, stored frozen at Ϫ20°C, were available for retrospective analysis. Samples were analyzed by the Sabin-Feldman test, 11 and Toxoplasma-specific antibodies were detected using commercially available enzyme immunoassays (IMx-IgG, Abbott, Wiesbaden, Germany; VIDAS-IgM, BioMérieux, Marcy l'Etoile, France; PlateliaIgA, Sanofi-Pasteur, Freiburg, Germany).
DNA extraction
For patients UPN 596 and 639, samples of formalin-fixed tissue (ie heart, brain, lung, intestine, spleen, liver and bone marrow) were removed from the fixative, stored at 4°C and allowed to dry for at least 1 week. Pieces of about 20-40 mg of the dried tissues were then pulverized with a pestle and suspended in 400 l TE9 lysis buffer 12 supplemented with 1% SDS and 2 mg/ml proteinase K (Merck, Darmstadt, Germany) and were incubated at 55°C overnight. The amount of proteinase K was then increased to a final concentration of 6 mg/ml and the incubation was continued for another 24 h. During this incubation procedure, the samples were vortexed extensively several times. For patient UPN 676, unfixed native tissue was obtained at autopsy, cut into small pieces and lysed in TE9 lysis buffer as described.
Two hundred microliters of the lysate were submitted to a DNA extraction procedure with spin columns (QIAamp Blood Kit, Qiagen, Hilden, Germany) following the instructions of the manufacturer. Alternatively, a tissue DNA extraction kit (NucleoSpin CϩT, Macherey-Nagel, Düren, Germany) was used for some samples. In order to exclude possible false negative results, 200 l aliquots of the lysates were spiked before DNA extraction with 25 or 50 toxoplasmic cells (BK strain) derived from the peritoneum of infected NMRI mice. Infection and maintenance of these mice was done as described 10 (obtained from the Zentrallabor für das Bundesamt für gesundheitlichen Verbraucherschutz und Veterinärmedizin, Berlin, Germany). For all three patients, serum and CSF samples were treated with the QIAamp Blood Kit.
Polymerase chain reaction
PCR was performed in a total volume of 50 l containing 1 U of DyNAzyme polymerase (Biometra, Göttingen, Germany), 0.2 mm of each dNTP, 0.5 m of each primer and 2.5 mm of MgCl 2 in reaction buffer. 13 Toxoplasma target genes for PCR were the B1 gene 14 and a 18S ribosomal DNA gene. 15 The B1 gene sequence was amplified for 40 cycles using primers P7/P8 14 corresponding to positions 864 to 883 and 694 to 714 of the gene, respectively, and leading to a PCR product of 190 bp. Ribosomal DNA was amplified under the same conditions and with primers TG IIb and TG III, published by Cazenave et al. 16 The resulting product had a size of 88 bp.
For nested PCR experiments with the B1 gene as a target, a first amplification was performed after initial denaturation for 5 min at 95°C for 35 cycles (95°C for 30 s, 55°C for 10 s and 70°C for 100 s) with primers P3 and P7B (positions 661 to 680 and 868 to 887), which yielded a product of 227 bp as a target for inner primers P7/P8. After the first 35 cycles, 1 l of the sample was transferred into 49 l of fresh master mix containing the inner primer pair and the procedure was repeated.
PCR products were detected after gel electrophoresis (100 V, 70 min, 2% MetaPhor agarose, BIOzym, Hess,
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Oldendorf, Germany) and visualized by staining with ethidium bromide. To check for false positive reactions or contaminations, two negative controls were included in each experiment using sterile water and EDTA blood from a healthy volunteer tested negative for T. gondii IgG and IgM and were subjected to the DNA extraction procedure described above. No PCR product was obtained with the negative controls in any experiment.
Histology and immunohistochemistry
At autopsy, several specimens were taken from brain, heart, lungs, intestine, liver, spleen and bone marrow. Also, biopsies were taken from all macroscopically suspicious areas. Tissues were fixed in 5% formalin and embedded in paraffin. Sections (4 m) were cut and stained with hematoxylin/eosin, and in part also with the periodic acidSchiff (PAS) reaction and trichrome light-green (Masson stain).
Immunohistochemistry was performed using a standard alkaline phosphatase-anti alkaline phosphatase (APAAP) method after pronase treatment. For detection of T. gondii, a polyclonal antibody directed against whole T. gondii parasites (Quartett, Berlin, Germany) was used. CMV-infected cells were detected by use of a combination of a monoclonal mouse antibody against the CMV immediate-early antigen (clone E13; Paesel ϩ Lorei, Hanau, Germany) and a mouse anti-CMV antibody against the delayed early DNA-binding protein p52 (clone CCH2; Dako, Glostrup, Denmark). Each antibody was diluted appropriately in Tris buffer (Dako ChemMate Antibody Diluent; Dako).
Results
Serology
Serial serology data for specific IgG showed a decline in the amount of serum IgG against T. gondii down to the cutoff level of the test, which was 3 IU/ml, in patients UPN 596 and 676, respectively. Specific IgM was consistently below the limit of detection in every patient. In patient UPN 676, specific IgA became positive from day ϩ41 post BMT. In all other patients, specific IgA was below the limit of detection throughout the respective observation period. Titers in the SFT were 1:256 in every patient before BMT and declined to 1:64 in case 1 at day ϩ55 post BMT, in case 2 at day 0 and in case 3 at day ϩ6 post BMT, respectively.
Polymerase chain reaction
The PCR results obtained with DNA extracted from the histological material are summarized in Table 2 . Of the 18 organs investigated, 11 (61%) were positive with immunohistochemistry, and nine (50%) yielded positive PCR results with both target genes. Five organs (28%) gave positive PCR results with either one of the target genes used. In only two organs (11%), no parasites could be detected either by immunohistochemistry or by one of the PCR systems (Table 2) . With specimens derived from lungs, intes- 
Immunohistochemistry was positive for CMV-antigen. ϩ = positive result; Ϫ = negative result; ND = not done due to lack of material.
tine, and heart of patient UPN 596, positive and reproducible PCR results could be obtained with primers for both target genes. DNA from spleen and liver of patient UPN 596 and from intestine, liver, and lungs of patient UPN 639 also showed positive signals after PCR of one target gene. However, these results were not reproduced with the respective second test system. Patient UPN 676 showed reproducible PCR results from brain, lungs, spleen and bone marrow. All samples gave positive signals when being spiked with 25 or 50 toxoplasmic cells before DNA extraction. Retrospectively, some of the formalin-fixed samples from UPN 596 and UPN 639 were tested with a nested PCR procedure for the B1 gene recently developed in our laboratory. With this method, eight out of nine samples were positive for Toxoplasma DNA which otherwise gave contradictory results either by immunohistochemistry or between the two target genes by conventional PCR (Table  2) . Unfortunately, DNA from 11 samples was no longer available for testing with nested PCR.
Conventional histology
Using hematoxylin/eosin as well as Masson staining and the PAS reaction, multiple large foci of cerebral necrosis were seen in patients UPN 596 and 676, respectively. Within the necrotic areas as well as within vital tissue next to the necroses, multiple pseudocysts of T. gondii and isolated tachyzoits could be detected. In patient UPN 596, there were also multiple small areas of necrosis in lungs, liver, and spleen containing pseudocysts and isolated organisms of T. gondii. We also found single tachyzoits in the bone marrow of patient UPN 596; patient UPN 676 showed isolated organisms within the liver. In patient UPN 639, pseudocysts of T. gondii were found within vital tissue of the lungs, liver, and bone marrow; and isolated tachyzoits were detected in the intestinal mucosa. All three patients showed only a slight inflammatory reaction, if any, in the affected regions.
Comparison of immunohistochemistry with PCR results
Viewed separately, immunohistochemistry alone demonstrated parasites in 13 out of 20 organs investigated (65%), whereas PCR gave signals with either one or both systems in 15 out of 20 organs (75%). Immunohistochemistry revealed results concordant to PCR data in 60% of the specimens (12 organs, four of which were positive in both PCR systems and in immunohistochemistry, six of which were positive in at least one PCR system and in immunohistochemistry, and two of which were found to be negative with all three methods) ( Table 2 ). When PCR was positive in both or either one of the systems, immunohistochemistry did not detect any parasites in five out of 20 organs investigated (25%). In three specimens (15%), immunohistochemistry demonstrated the presence of parasites when PCR did not yield an amplification product in either system. When used together, however, PCR or immunohistochemistry demonstrated the presence of parasites in 18 of 20 specimens (90%). The use of a nested PCR protocol for the B1 gene detected toxoplasmic DNA in eight of nine samples (89%), and two of three samples, which were negative with conventional PCR but positive by immunohistochemistry, were positive by nested PCR (brains of patients 596 and 639).
Discussion
Toxoplasmosis is a rare, but serious complication following BMT. It occurs as early as 30 days after BMT (our patient UPN 639) as well as being a late complication up to 12 months after BMT. 9 The prevalence depends, among other variables, on the frequency of autopsies performed and on the diagnostic acumen of the physicians. For example, in the largest series of patients reported, diagnosis was made intra vitam in only two out of 12 patients (17%). 3 The second series, however, reported a diagnosis made during life in five out of seven patients by demonstration of the parasites in the blood, CSF and BAL in three out of seven patients and improvement after therapy with pyrimethamine/sulfadiazine in three out of seven patients as a diagnostic indicator. 7 In our patients, diagnosis was suggested by clinical signs and typical CT scans of the brain in patients UPN 596 and 676, whereas in patient UPN 639 the diagnosis was made at autopsy. There was no demonstration of parasites during the clinical course despite various invasive diagnostic procedures in patient UPN 676. Definitive diagnosis was made in all patients at autopsy by demonstration of parasites and their DNA using both immunohistochemistry and PCR.
Invasive procedures in BMT recipients carry a high risk for complications, and non-invasive methods for detection of T. gondii have long been sought. Although serology is generally considered not to be helpful in BMT recipients, one report discusses the value of declining IgG antibody titers in a case of disseminated toxoplasmosis speculating that this might have been due to the short half life of circulating specific antibodies during active infection and the not yet optimal production of these antibodies. 17 Two of our patients who survived long enough after BMT displayed the same phenomenon of declining IgG antibody titers. This observation, however, requires confirmation by large numbers of patients before diagnostic clues can be obtained from serology after BMT.
Other diagnostic methods rely on the demonstration of the parasite in tissue specimens or BAL either by direct visualization of the parasites 18 or by tissue culture methods using peripheral blood buffy coat cells 6 and BAL, 18 respectively. Disadvantages of these approaches are either low parasite density resulting in decreased sensitivity when direct visualization is used or the delay of diagnosis with tissue culture methods. Recently, PCR has been used to facilitate the detection of T. gondii. 9 Although T. gondii has been detected by PCR in blood and buffy coat specimens, 1 in all three patients reported here, PCR in serum was consistently negative with the exception of patient UPN 596, where it became positive 2 days prior to his death. It may be possible that T. gondii is separated from the serum, along with the cellular blood components, by centrifugation. In a prospective study, we now investigate whole EDTA blood for the presence of T. gondii DNA after BMT using the nested PCR technique described above. Indeed, by using whole blood rather than serum, we were able to detect parasitemia in a number of patients during their course after BMT. At this stage, however, this approach is still investigational, and any conclusions about the routine use of PCR of whole blood for monitoring patients at risk would be premature.
Poor quality template DNA due to fixation of tissues with formalin 19 may be a reason for discrepancies when comparing negative PCR results with positive immunohistochemical findings. On the other hand, a positive DNA amplification which does not correlate with immunohistochemistry (eg intestine samples of patient UPN 596 and lung and spleen samples of patient UPN 676) may be due to the higher sensitivity of the PCR method. A false positive result due to carryover contamination is unlikely because precautions were strictly followed in our laboratory 20 and because a positive result with the negative controls was never observed. Contamination, however, may have occurred during autopsy, sample handling, or sample storage in close contact with other tissues containing specific DNA. 21 Furthermore, it should be mentioned that in patient UPN 596, a positive PCR result for Toxoplasma was obtained in serum 2 days before death. Hence, contamination of the intestine with toxoplasmic DNA via the bloodstream can not be excluded in this patient. This is, to our knowledge, the first report comparing two methods of diagnosing toxoplasmosis after BMT side-byBone Marrow Transplantation side. Our results indicate that PCR may have the potential to be a definitive diagnostic procedure in combination with immunohistochemistry. Neither method, when used alone, was able to detect parasites in all tissues investigated. When used together, however, the presence of parasites was detected in 90% of the specimens. The use of a more sensitive nested PCR procedure may further increase the sensitivity. New protocols are currently evaluated in our laboratory to improve the reproducibility of this method when working with formalin-fixed samples. 22 
